The human microbiota has been extensively associated with multiple immune-related illnesses, including autoimmunity, IBD, and cancer. Nevertheless, much less is known about the exact, causative mechanisms by which these microorganisms control disease outcomes. Our lab develops technologies rooted in chemical biology to discover the molecular, receptor, and cellular components that allow microbes to influence host immune sensing and activation. We currently focus on the diverse family of glycans found in microbial cell walls as broad agents to elicit systemic priming of the myeloid cell compartment, with the overarching goal to understand, predict, and augment individual responses to cancer immunotherapies through our synthetic reagents and methods.